Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Teprotide is a nonapeptide originally isolated from the venom of the Brazilian pit viper, *Bothrops jararaca*. It functions as an angiotensin-converting enzyme (ACE) inhibitor, blocking the conversion of angiotensin I to angiotensin II and potentiating the pharmacological actions of bradykinin. Although it demonstrated significant antihypertensive effects, its clinical utility was limited due to its peptide nature, requiring parenteral administration, its expense, and lack of oral activity. Teprotide played a crucial role as a lead compound in the rational design and development of the first orally active ACE inhibitors, such as captopril.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on teprotide.